Modulators of CFTR. Updates on clinical development and future directions.

European journal of medicinal chemistry 2021 Mar 05

filter terms:

Cystic fibrosis (CF) is the most frequent life-limiting autosomal recessive disorder in the Caucasian population. It is due to mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Current symptomatic CF therapies, which treat the downstream consequences of CFTR mutations, have increased survival. Better knowledge of the CFTR protein has enabled pharmacologic therapy aiming to restore mutated CFTR expression and function. These CFTR "modulators" have revolutionised the CF therapeutic landscape, with the potential to transform prognosis for a considerable number of patients. This review provides a brief summary of their mechanism of action and presents a thorough review of the results obtained from clinical trials of CFTR modulators. Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Citation

Emmanuelle Bardin, Alexandra Pastor, Michaela Semeraro, Anita Golec, Kate Hayes, Benoit Chevalier, Farouk Berhal, Guillaume Prestat, Alexandre Hinzpeter, Christine Gravier-Pelletier, Iwona Pranke, Isabelle Sermet-Gaudelus. Modulators of CFTR. Updates on clinical development and future directions. European journal of medicinal chemistry. 2021 Mar 05;213:113195